Molecular pathology of vascular injury
Molecular pathology of vascular injury
批准号:
6931991
负责人:
Dario C Altieri
金额:
$32.4万
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-08-01 至 2009-07-31
关键词:
angiogenesisapoptosisbiological signal transductioncadherinscardiovascular injurycell growth regulationcell proliferationclinical researchconfocal scanning microscopycytoprotectionflow cytometrygene expressiongenetically modified animalshuman tissueimmunocytochemistrylaboratory mouseleukocyte activation /transformationmolecular pathologyplatelet derived growth factorprotein structure functionstem cellssurvivintissue /cell culturevascular endothelial growth factorsvascular endothelium
中文摘要
描述(由申请人提供):HL54131的中心主题是研究血管疾病的重要基因。在上一个资助周期中开展的工作主要集中在survivin作为血管生成内皮细胞凋亡和有丝分裂调节剂的高功能抑制剂。从这些实验中产生了三个新的范例,构成了目前继续应用的基础。首先,survivin被确定为平滑肌细胞pdgf依赖性存活的介质,在体内对survivin通路的分子干扰可阻止急性动脉损伤后的病理性血管重塑。其次,survivin抑制细胞凋亡的机制与线粒体细胞死亡的上游起始有关,并且一个离散的survivin池被证明定位于线粒体。第三,survivin被认为是一种由Wnt/TCF/ β -catenin诱导的新型细胞保护因子,这是一种保持组织干细胞和骨髓祖细胞多能性的基因模式通路。因此,可以形成一个统一的假设,即survivin在血管损伤期间维持平滑肌细胞及其祖细胞的稳态,并将在本研究的继续应用中进行研究。在第一个具体目标中,实验将绘制PDGF诱导平滑肌细胞中生存素的结构和信号要求。这是一种生长因子特异性途径,其特征包括Wnt/TCF/ β -连环蛋白基因表达、细胞周期蛋白依赖性激酶抑制剂的调节、ERK信号传导、PI3激酶/Akt的激活和STAT磷酸化。第二个具体目标将剖析线粒体survivin在细胞凋亡抑制中的作用,探讨线粒体运输、通透性转变、凋亡细胞组装和增强的lap依赖性细胞保护的机制。第三个具体目标是确定survivin在骨髓和平滑肌细胞祖细胞的细胞活力、增殖和集落形成中的重要性。该通路对急性动脉损伤后病理性血管重构的影响将在骨髓移植实验中通过转基因或逆转录病毒操纵祖细胞中survivin的表达/功能来确定。总的来说,实验计划旨在阐明急性血管损伤期间平滑肌细胞稳态的新生存途径。
英文摘要
DESCRIPTION (provided by applicant): The central theme of HL54131 is to study genes of importance in vascular diseases. Work carried out during the previous grant cycle focused on survivin as a hi-functional inhibitor of apoptosis and mitotic regulator in angiogenic endothelium. Three new paradigms emerged from these experiments that constitute the foundation of the present continuation application. First, survivin was identified as a mediator of PDGF-dependent survival in smooth muscle cells, and molecular interference with the survivin pathway prevented pathologic vascular remodeling after acute arterial injury, in vivo. Second, the mechanism of apoptosis inhibition by survivin was linked to the upstream initiation of mitochondrial cell death, and a discrete pool ot survivin was shown to localize to mitochondria. Third, survivin was characterized as a novel cytoprotective factor induced by Wnt/TCF/beta-catenin, a gene patterning pathway that preserves the pluripotency of tissue stem cells and bone marrow progenitors. Therefore, a unifying hypothesis that survivin maintains the homeostasis of smooth muscle cells and their progenitors during vascular injury can be formulated, and will be investigated in the present continuation application. In the first specific aim, experiments will map the structural and signaling requirements of PDGF induction of survivin in smooth muscle cells. This is a growth factor-specific pathway and will be characterized with respect to Wnt/TCF/beta-catenin gene expression, modulation of cyclin-dependent kinase inhibitors, ERK signaling, activation of PI3 kinase/Akt, and STAT phosphorylation. The second specific aim will dissect the role of mitochondrial survivin in apoptosis inhibition, addressing mechanisms of mitochondrial trafficking, permeability transition, apoptosome assembly, and enhanced lAP-dependent cytoprotection. The third specific aim will determine the importance of survivin in cell viability, proliferation, and colony formation of bone marrow and smooth muscle cell progenitors. The impact of this pathway in pathologic vascular remodeling after acute arterial injury will be determined in bone marrow transplantation experiments using transgenic or retroviral manipulation of survivin expression/function in progenitor cells. Overall, the experimental plan is designed to elucidate a novel survival pathway central to smooth muscle cell homeostasis during acute vascular injury.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Augmenting T-cell immunotherapy outcomes in blood and solid tumor microenvironment in ART-suppressed HIV infection (immune/microenvironment)
-
批准号:10620011
-
项目类别:
-
资助金额:$12.42万
-
财政年份:2022
-
负责人:Dario C Altieri
-
依托单位:
A First-in-Human Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib
-
批准号:10472429
-
项目类别:
-
资助金额:$31.63万
-
财政年份:2021
-
负责人:Dario C Altieri
-
依托单位:
A First-in-Human Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib
-
批准号:9668658
-
项目类别:
-
资助金额:$41.03万
-
财政年份:2021
-
负责人:Dario C Altieri
-
依托单位:
Tumor Plasticity
-
批准号:10474434
-
项目类别:
-
资助金额:$111.72万
-
财政年份:2017
-
负责人:Dario C Altieri
-
依托单位:
Tumor Plasticity
-
批准号:10248385
-
项目类别:
-
资助金额:$114.0万
-
财政年份:2017
-
负责人:Dario C Altieri
-
依托单位:
Tumor Plasticity
-
批准号:9767084
-
项目类别:
-
资助金额:$110.42万
-
财政年份:2017
-
负责人:Dario C Altieri
-
依托单位:
Tumor Plasticity
-
批准号:10684678
-
项目类别:
-
资助金额:$111.72万
-
财政年份:2017
-
负责人:Dario C Altieri
-
依托单位:
Tumor Plasticity
-
批准号:9538612
-
项目类别:
-
资助金额:$114.0万
-
财政年份:2017
-
负责人:Dario C Altieri
-
依托单位:
Molecular and Cellular Oncogenesis
-
批准号:8690263
-
项目类别:
-
资助金额:$3.77万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Planning and Evaluation
-
批准号:8690274
-
项目类别:
-
资助金额:$3.53万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
(PQC2) Plasticity Of The.PI3K Network In Early Dormancy
-
批准号:8791730
-
项目类别:
-
资助金额:$38.39万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Genomics
-
批准号:8932921
-
项目类别:
-
资助金额:$21.48万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Bioinformatics Shared Resources
-
批准号:8690292
-
项目类别:
-
资助金额:$22.14万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Gene Expression
-
批准号:8689270
-
项目类别:
-
资助金额:$4.18万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Developmental Funds
-
批准号:8690275
-
项目类别:
-
资助金额:$44.68万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
IMAGING SHARED RESOURCE
-
批准号:8689269
-
项目类别:
-
资助金额:$7.59万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Proteomics Shared Resource
-
批准号:8932923
-
项目类别:
-
资助金额:$18.74万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Animal Facility Shared Resources
-
批准号:8690265
-
项目类别:
-
资助金额:$25.87万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Molecular Screening Shared Resource
-
批准号:8932922
-
项目类别:
-
资助金额:$18.81万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
(PQC2) Plasticity Of The.PI3K Network In Early Dormancy
-
批准号:9112948
-
项目类别:
-
资助金额:$39.43万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
-
批准号:31970691
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:张胜萍
-
依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
-
批准号:31900527
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:孙磊
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
姜黄素与TRAIL的协同抗肿瘤机制研究
-
批准号:31101223
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2011
-
负责人:曹林
-
依托单位:
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
-
批准号:81100502
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:管娜
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位: